Anton Florin Ioan, Rus Paul Adrian, Hagau Natalia
Regina Maria Hospital, Cluj-Napoca, Romania.
Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Emergency Clinical County Hospital, Cluj-Napoca, Romania.
J Crit Care Med (Targu Mures). 2020 Aug 11;6(3):159-166. doi: 10.2478/jccm-2020-0024. eCollection 2020 Jul.
Controlled anticoagulation is key to maintaining continuous blood filtration therapies. Objective: The study aimed to compare different blood sampling sites for activated partial thromboplastin time (aPTT) to evaluate anticoagulation with unfractionated heparin (UFH) in continuous renal replacement therapy (CRRT) and identify the most appropriate sampling site for safe patient anticoagulation and increased filter life span.
The study was a prospective observational single-centre investigation targeting intensive care unit (ICU) patients on CRRT using an anticoagulation protocol based on patient characteristics and a weight-based modified nomogram. Eighty-four patients were included in the study. Four sampling sites were assessed: heparin free central venous nondialysis catheter (CVC), an arterial line with heparinised flush (Artery), a circuit access line (Access), and a circuit return line (Postfilter). Blood was sampled from each of four different sites on every patient, four hours after the first heparin bolus. aPTT was determined using a rapid clot detector, point of care device.
A high positive correlation was obtained for aPTT values between CVC and Access sampling sites (r (84) =0.72; p <0 .05) and a low positive correlation between CVC and Arterial sampling site (r (84) =0.46, p < 0.05). When correlated by artery age, the young Artery (1-3 day old) correlates with CVC, Access and Postfilter (r (45) = 0.74, p >0.05). The aPTT values were significantly higher at Postfilter and Arterial sampling site, older than three days, compared to the CVC sampling site (p<0.05).
Considering patient bleeding risks and filter life span, the optimal sampling sites for safe assessment of unfractionated heparin anticoagulation on CRRT during CVVHDF were the central venous catheter using heparin free lavage saline solution, a heparinised flushed arterial catheter not older than three days, and a circuit access line.
控制抗凝是维持连续性血液滤过治疗的关键。目的:本研究旨在比较不同采血部位活化部分凝血活酶时间(aPTT),以评估连续性肾脏替代治疗(CRRT)中普通肝素(UFH)的抗凝效果,并确定最适合的采血部位,以实现患者安全抗凝并延长滤器使用寿命。
本研究是一项前瞻性单中心观察性研究,针对接受CRRT的重症监护病房(ICU)患者,采用基于患者特征和体重修正列线图的抗凝方案。84例患者纳入研究。评估了四个采血部位:无肝素中心静脉非透析导管(CVC)、含肝素封管液的动脉管路(动脉)、体外循环管路入口端(入口)和体外循环管路回输端(滤器后)。在首次给予肝素推注4小时后,从每位患者的四个不同部位采集血液样本。使用快速凝血检测仪(即时检测设备)测定aPTT。
CVC和入口采样部位的aPTT值具有高度正相关性(r(84)=0.72;p<0.05),CVC与动脉采样部位的aPTT值呈低度正相关(r(84)=0.46,p<0.05)。按动脉管路使用时长进行相关性分析时,新的动脉管路(使用1 - 3天)与CVC、入口和滤器后部位相关(r(45)=0.74,p>0.05)。与CVC采样部位相比,使用超过三天的动脉采样部位和滤器后部位的aPTT值显著更高(p<0.05)。
考虑到患者出血风险和滤器使用寿命,在连续性静脉 - 静脉血液透析滤过(CVVHDF)期间,安全评估CRRT中普通肝素抗凝效果的最佳采样部位为使用无肝素冲洗生理盐水的中心静脉导管、使用不超过三天的含肝素封管液的动脉导管以及体外循环管路入口端。